# Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

> **NCT04550325** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kamada, Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Covid19
- Pneumonia, Viral

## Interventions

- **BIOLOGICAL:** Kamada Anti-SARS-CoV-2

## Key facts

- **NCT ID:** NCT04550325
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-05
- **Primary completion:** 2020-11-26
- **Final completion:** 2020-11-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550325, "Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04550325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*